B7-H3/FOLR1 dual targeting CAR-T / Fosun Kite - LARVOL DELTA

Fosun Kite Biotech obtains patent for the preparation and application of a dual-target CART targeting B7-H3 and FOLR1, covering a wider range of ovarian cancer tumor cells [Google translation] (163.com) - "According to a report in the financial sector on September 8, 2024, Tianyancha intellectual property information shows that Fosun Kite Biotechnology Co., Ltd. has obtained a patent called 'Preparation and Application of a Dual Target CART Targeting B7-H3 and FOLR1', with authorization announcement number CN115491358B and application date of June 2021. The patent abstract shows that the present invention provides a chimeric antigen receptor CAR-immune cell and its application that can target the dual targets of FOLR1 and B7-H3. The application of the CAR-T cells of the present invention can cover a wider range of ovarian cancer tumor cells."

Patent • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

OmRx Oncology Launches to Advance Investigational Oral Checkpoint Inhibitor Designed to Increase Access to Cancer Immunotherapy Worldwide (Businesswire) - "OmRx Oncology, or 'OmRx,' a new biopharmaceutical venture with investment from Scripps Research, launched with a Phase 2 clinical asset in-licensed from Gilead Sciences, Inc. and a vision for expanding access to immunotherapy in countries where biologic checkpoint inhibitors are often unaffordable and unavailable to patients...OmRx in-licensed the Phase 2-ready asset and plans to develop it for patients in countries where an oral small molecule would present a more affordable, accessible, and potentially equally effective option to traditional antibody checkpoint inhibitors such as Keytruda and Opdivo...OX-4224 will initially be studied as a second-line monotherapy in patients with metastatic NSCLC whose tumors express PD-L1. The Phase 2 randomized, open-label study in India will establish safety and efficacy of OX-4224 in subjects with NSCLC who have not received immune checkpoint inhibitors."

New molecule • New P2 trial • Oncology • Solid Tumor